ImmunityBio Sued in Securities Class Action Over Anktiva Marketing Claims

Overview

• Robbins Geller Rudman & Dowd filed Douglas v. ImmunityBio in federal court in California and is inviting investors to seek lead‑plaintiff status.
• The complaint says company leaders called Anktiva a cancer vaccine and suggested it would keep all NMIBC patients cancer‑free long term, claims it alleges are false.
• It cites an FDA letter to CEO Richard Adcock that said a TV ad and a podcast misbranded Anktiva, a bladder cancer drug, in violation of federal law.
• The filing says investors lost money when the letter became public and ImmunityBio’s shares fell about 21 percent.
• Under the securities law process, a court appoints a lead plaintiff to act for the class and that investor then chooses the law firm.